Compare PROV & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PROV | MCRB |
|---|---|---|
| Founded | 1956 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.7M | 85.7M |
| IPO Year | 2009 | 2015 |
| Metric | PROV | MCRB |
|---|---|---|
| Price | $17.16 | $7.75 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $16.25 | $14.00 |
| AVG Volume (30 Days) | 7.8K | ★ 43.4K |
| Earning Date | 04-28-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.26% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.47 | ★ 0.64 |
| Revenue | N/A | ★ $789,000.00 |
| Revenue This Year | $4.14 | N/A |
| Revenue Next Year | $3.70 | N/A |
| P/E Ratio | $36.51 | ★ $12.06 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.85 | $6.56 |
| 52 Week High | $17.42 | $29.98 |
| Indicator | PROV | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 68.77 | 40.36 |
| Support Level | $15.63 | N/A |
| Resistance Level | $17.35 | $9.53 |
| Average True Range (ATR) | 0.22 | 0.57 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 50.00 | 45.49 |
Provident Financial Holdings Inc is a holding company of Provident Savings Bank, F.S.B. It is a financial services company committed to serving consumers and small to mid-sized businesses in the Inland Empire region of Southern California. Its business activities consist of community banking, investment services and trustee services for real estate transactions. The group operates in Bank segment that include attracting deposits, offering banking services and originating and purchasing single-family, multi-family, commercial real estate, construction and, to a lesser extent, other mortgage, commercial business and consumer loans. Its evenues are derived from interest earned on its loan and investment portfolios, and fees generated through its community banking activities.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.